Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists

Author:

Song Rui1,Qian Hang1,Wang Yunlian1,Li Qingmei1,Li Dongfeng1,Chen Jishun1,Yang Jingning2,Zhong Jixin3ORCID,Yang Handong1,Min Xinwen1,Xu Hao1ORCID,Yang Yong1ORCID,Chen Jun1245ORCID

Affiliation:

1. Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China

2. Department of Immunology, School of Basic Medicine, Hubei University of Medicine, Shiyan, Hubei 442000, China

3. Department of Rheumatology and Immunology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China

4. Hubei Key Laboratory of Wudang Local Chinese Medicine Research (Hubei University of Medicine), China

5. Institute of Virology, Hubei University of Medicine, Shiyan, Hubei 442000, China

Abstract

The risk of cardiovascular diseases is closely related to diabetes. Macrovascular disease is the main cause of death and disability in patients with type 2 diabetes. In recent years, the glucagon-like peptide-1 receptor agonist (GLP-1RA), a new type of hypoglycemic drug, has been shown to regulate blood sugar levels, improve myocardial ischemia, regulate lipid metabolism, improve endothelial function, and exert a protective role in the cardiovascular system. This study reviewed the protective effects of GLP-1RA on the cardiovascular system.

Funder

Hubei Key Laboratory of Wudang Local Chinese Medicine Research

Publisher

Hindawi Limited

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3